Provides an overview of calcium-antagonist drugs and their chemical heterogeneity in the treatment of cardiovascular disease.
Answers are grounded in this paper and cite their sources.
May inform calcium antagonist selection by chemical properties; leaves open need for comparative outcome trials.
THE use of a group of drugs collectively referred to as "calcium antagonists," "slow channel antagonists," or "calcium-channel blockers" is likely to increase in the coming years. Currently, calcium antagonists are used primarily in the treatment of cardiovascular disease, and only three of these drugs —nifedipine, verapamil, and diltiazem — are available in the United States. However, numerous others that are already available to European clinicians are likely to be used in this country in the near future.One of the most striking aspects of the calcium-antagonist drugs is their chemical heterogeneity (Fig. 1). Many of these drugs were developed . . .
No takes yet. Share an insight, caveat, or question.
Flier et al. (1985) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: